Unity Biotechnology Stock Today
Unity Biotechnology is trading at 0.16 as of the 19th of July 2025; that is 6.67 percent increase since the beginning of the trading day. The stock's open price was 0.15. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of May 2018 | Category Healthcare | Classification Health Care |
Unity Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsUnity Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Unity Biotechnology's financial leverage. It provides some insight into what part of Unity Biotechnology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unity Biotechnology (UBX) is traded on NASDAQ Exchange in USA and employs 16 people. Unity Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a total capitalization of 3.44 M. Unity Biotechnology runs under Biotechnology sector within Health Care industry. The entity has 17.21 M outstanding shares of which 572.5 K shares are at this time shorted by investors with about 1.09 days to cover.
Unity Biotechnology has about 64.51 M in cash with (20.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Unity Biotechnology Probability Of Bankruptcy
Unity Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Cercano Management Llc | 2025-03-31 | 41.2 K | |
| State Street Corp | 2025-03-31 | 37.8 K | |
| Northern Trust Corp | 2025-03-31 | 35.5 K | |
| Simplex Trading, Llc | 2025-03-31 | 30.9 K | |
| Group One Trading, Lp | 2025-03-31 | 28.6 K | |
| Seacrest Wealth Management, Llc | 2025-03-31 | 27.8 K | |
| Commonwealth Equity Services Inc | 2025-03-31 | 26.1 K | |
| Ubs Group Ag | 2025-03-31 | 24.3 K | |
| Virtu Financial Llc | 2025-03-31 | 18 K | |
| Arch Venture Corp | 2025-03-31 | 1 M | |
| Vanguard Group Inc | 2025-03-31 | 673.1 K |
Unity Biotechnology Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Unity Biotechnology market risk premium is the additional return an investor will receive from holding Unity Biotechnology long position in a well-diversified portfolio.
| Mean Deviation | 5.57 | |||
| Standard Deviation | 9.29 | |||
| Variance | 86.31 | |||
| Risk Adjusted Performance | (0.21) |
Unity Stock Against Markets
Unity Biotechnology Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Unity Biotechnology stock to make a market-neutral strategy. Peer analysis of Unity Biotechnology could also be used in its relative valuation, which is a method of valuing Unity Biotechnology by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Unity Biotechnology Corporate Management
| Dr AB | CoFounder Director | Profile | |
| Nathan Guz | Vice Operations | Profile | |
| Judith Campisi | Founder | Profile | |
| Daohong MD | Founder | Profile | |
| Anirvan Ghosh | CEO Director | Profile | |
| Jamie MD | Chief Officer | Profile |
Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.